Fc-Specific Peptides Expand Regulatory T Cells for Vascular Homeostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Kawasaki disease, such as IVIG therapy, are expensive and not viable in third-world regions, and they fail to expand Fc-specific natural regulatory T cells (nTregs) in patients who develop coronary artery abnormalities, indicating a need for alternative immunotherapies that can effectively expand nTregs to maintain vascular homeostasis.
Innovation Solution
Development of isolated, synthetic, or recombinant peptides that mimic the Fc region of immunoglobulin G, capable of generating Fc-specific nTregs to suppress pro-inflammatory T cell responses, which can be administered alone or combined with other immunomodulatory agents to treat autoimmune and inflammatory vascular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IVIG therapy is used to treat Kawasaki disease, then vascular homeostasis is maintained in most patients, but the treatment is expensive and requires hospitalization
Solution Approach 1:
The patent extracts the essential therapeutic function of IVIG (expansion of Fc-specific nTregs) by using only the Fc region of IgG as a standalone therapeutic agent. This extracted component maintains the ability to expand nTregs while eliminating the need for expensive whole immunoglobulin preparations and hospitalization requirements
Solution Approach 2:
The patent creates simplified copies of the therapeutic mechanism by using Fc fragments and Fc-specific peptides that replicate the nTreg-expanding function of whole IVIG therapy. These copies provide the same immunological effect at a fraction of the cost and with simplified administration
2Reliability
If IVIG therapy is administered, then Fc-specific nTregs are expanded in responsive patients, but the therapy fails to expand nTregs in patients who develop coronary artery abnormalities
Solution Approach 1:
The patent applies local quality by using Fc-specific peptides that target the precise epitope recognized by Fc-specific nTregs. This localized targeting ensures consistent activation of the specific Treg population needed for vascular homeostasis, overcoming the variable response seen with whole IVIG therapy
Solution Approach 2:
The patent changes the physical and chemical parameters of the therapeutic agent by using purified Fc fragments and specific peptides instead of whole immunoglobulins. This parameter change (from complex protein mixture to defined molecular structure) enables more reliable and predictable nTreg expansion across all patients
3Reliability
If Fc-specific nTregs are expanded to suppress pro-inflammatory T cell responses, then vascular homeostasis is maintained, but the mechanism requires understanding of complex immune interactions
Solution Approach 1:
The patent extracts the essential Fc region from the complex immunoglobulin structure to create a simplified therapeutic agent. This extraction maintains the key immunological function (nTreg expansion) while removing unnecessary complexity from the treatment mechanism
Solution Approach 2:
The patent uses Fc-specific peptides as intermediaries that bridge the gap between the therapeutic agent and the immune system. These peptides serve as simple mediators that directly engage Fc-specific nTregs through well-defined interactions, simplifying the overall therapeutic mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively expand nTregs, providing a cost-effective alternative to IVIG therapy, capable of suppressing pro-inflammatory T cell responses and treating conditions like Kawasaki disease, atherosclerosis, and other autoimmune disorders by establishing or re-establishing vascular homeostasis.
Implementation Method 1
Fc-specific Treg are very relevant to maintain vascular homeostasis... the suppression mechanism of pro-inflammatory T cell responses (by Fc-specific nTreg) occur in the lymph nodes
Data Source
AI summary
Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and method for making and using them. Provided are immunotherapies for promoting expansion of natural, Treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; as immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (IVIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or Juvenile Idiopathic Arthritis; a neoplastic hematological disorder, or a leukemia.